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Research
ancer mortality rates are higher for
Indigenous Australians than for other
Australians for many specific cancer
sites. This is partly because of the higher
incidence of some cancers (particularly lung
and other smoking-related cancers, cervical
and liver cancers), and partly because of
lower survival for most cancers.1-3
Lower cancer survival rates for Indige-
nous people compared with non-Indigenous
people have been reported from South Aus-
tralia (for all cancers combined),4 and from
the Northern Territory (for most specific
cancers exa ined).3 Survival rates have not
been reported for Indigenous people else-
where in Australia.
In South Australia, Indigenous people
were more likely to have advanced disease at
diagnosis than non-Indigenous people (for
all cancers combined), but this explained
only part of the difference in survival.4 Stage
at diagnosis has not been reported for Indig-
enous people elsewhere in Australia, or for
individual cancer sites.
Our study investigated whether, in the
Northern Territory (NT), Indigenous people
with cancer had more advanced disease at
diagnosis than non-Indigenous people with
cancer, and whether later diagnosis explains
their lower cancer survival.
METHODS
All residents of the NT diagnosed with can-
cers of the colon and rectum (including
anus), lung, female breast, cervix or non-
Hodgkin lymphoma in 1991–2000 were eli-
gible for inclusion in this study. These five
cancers were chosen as they are designated
“priority” cancers in Australia, and as there
were sufficient numbers of both Indigenous
and non-Indigenous cases to enable compari-
son. Cases were identified from the NT Can-
cer Registry.5,6 Hospital and private
specialists’ medical records were examined to
collect data on stage at diagnosis and to verify
data obtained from the Registry, including
Indigenous status and cause of death.
Cancer staging
Cancer stage at diagnosis was classified
using the SEER summary staging system.7
This staging system was used as it is the only
system that applies to all five cancers
included in the study. It classifies cancers as
localised, regional or distant spread. Cancer
stage was also classified using the TNM
staging system (except for non-Hodgkin
lymphoma, to which TNM staging does not
apply) and site-specific staging systems
(Dukes for colorectal cancer, FIGO for cervi-
cal cancer and Ann Arbor for non-Hodgkin
lymphoma); results for these systems were
published elsewhere.8
Statistical analysis
The proportion of Indigenous and non-
Indigenous people with advanced disease
(regional or distant spread), adjusted for age
at diagnosis, was compared for each of the
five cancers.
For each cancer, Cox regression analysis
was used to estimate the stage-specific and
stage-adjusted hazard ratios (relative risks of
cancer death) and their 95% confidence
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intervals for Indigenous compared with non-
Indigenous people. Follow-up for death was
to 31 December 2002. Stage-adjusted, cause-
specific cancer survival rates were also esti-
mated from regression models. All regression
analyses included adjustment for age at diag-
nosis by individual year of age.
Because of empirical evidence for the
existence of important interacting effects,
regression models used to estimate stage-
specific hazard ratios included an interac-
tion term for Indigenous status by age at
diagnosis. Models used to estimate stage-
adjusted hazard ratios also included interac-
tion terms for Indigenous status by stage
and age by stage. Cox regression analysis of
cause-specific relative risk of cancer death
was used to analyse cancer survival rather
than relative survival because of the com-
plexity of these interactions. For the same
reason, the contribution of diagnosis with
more advanced disease to lower Indigenous
cancer survival could not be validly assessed
by comparing survival rates before and after
adjustment for stage at diagnosis. A more
detailed report of both analytical methods
and results is available elsewhere.8
The study was approved by the Menzies
School of Health Research Human Research
Ethics Committee (HREC), the Charles Dar-
win University HREC and the Central Aus-
tralian HREC.
RESULTS
We found that 1373 people were eligible for
inclusion; medical records containing details
of cancer diagnosis and treatment could not
be found for 165 of these, including 32 who
were recorded by the NT Cancer Registry as
Indigenous. This left 1208 participants in
the study (88% of those eligible).
Sufficient information was found in medi-
cal records to enable classification of SEER
summary stage at diagnosis for 1201 people
(99.4% of those for whom medical records
were available). Five of the seven patients
for whom stage at diagnosis could not be
determined were non-Indigenous (two with
colorectal cancer, one with lung cancer, and
two with breast cancer), and two were
Indigenous (both with lung cancer).
Cancer stage at diagnosis
Indigenous people with cancer of the colon
and rectum, breast, cervix, and non-Hodg-
kin lymphoma, were more likely to be diag-
nosed with advanced disease than non-
Indigenous people, although the difference
was not always statistically significant (Box
1). For all four cancers combined (adjusted
for cancer site and age at diagnosis), 70% of
Indigenous people were diagnosed with
advanced disease (95% CI, 62%–78%) com-
pared with 51% of non-Indigenous people
(95% CI, 53%–59%).
For lung cancer, Indigenous people were
less likely than non-Indigenous people to be
diagnosed with advanced disease (Box 1).
Cancer survival rates
With one exception (lung cancer with dis-
tant spread), the relative risk of cancer
death, adjusted for age at diagnosis, was
greater for Indigenous than for non-Indige-
nous people in each category of stage at
diagnosis for each cancer site, although not
all 95% confidence intervals excluded 1.0
(Box 2). The stage-adjusted relative risk of
cancer death was significantly greater in
Indigenous than non-Indigenous people for
each cancer site.
These differences were reflected in a lower
age- and stage-adjusted 5-year cause-spe-
cific cancer survival rate in Indigenous peo-
ple compared with non-Indigenous people
for each cancer site (Box 3).
DISCUSSION
Between 1991 and 2000 in the NT, Indige-
nous people with cancer of the colon and
rectum, breast, cervix and non-Hodgkin
lymphoma were more likely to be diagnosed
with advanced disease than non-Indigenous
people. Only for cancer of the lung were
Indigenous people less likely to be diag-
nosed with advanced disease than non-
Indigenous people.
Cancer survival was lower for Indigenous
patients than non-Indigenous patients for all
five cancer sites examined and, with few
exceptions, for each stage at diagnosis for
2 Relative risk (RR) of cancer death for Indigenous versus non-Indigenous 
patients by cancer site and stage at diagnosis 
Age-adjusted RR (95% CI) Age- and stage-
adjusted  RR 
(95% CI)Cancer site Localised Regional Distant
Colon and rectum na 6.9 (3.6–13.1) 2.0 (0.8–4.6) 6.5 (3.7–11.3)
Lung 1.4 (0.9–2.1) 1.8 (1.1–3.0) 0.8 (0.5–1.2) 1.4 (1.1–1.8)
Breast 2.1 (0.5–9.3) 2.7 (1.2–6.4) 2.7 (0.8–9.5) 2.4 (1.1–5.2)
Cervix 2.1 (0.7–6.0) 6.5 (1.7–25.5) na 3.0 (1.4–6.2)
Non-Hodgkin 
lymphoma
na 2.5 (0.5–12.2) 8.5 (2.9–24.4) 5.2 (2.2–11.9)
na = not available: there were insufficient numbers of cancer deaths to estimate relative risks in these 
categories.
1 Number of cases and proportion with advanced disease* at diagnosis among 
people diagnosed with cancer in the Northern Territory, 1991–2000
Total cases† Proportion with advanced disease (95% CI)‡
Cancer site Indigenous
Non-
Indigenous Indigenous
Non-
Indigenous P§
Colon and rectum 34 268 89% (80%–99%) 68% (62%–83%) 0.05
Lung 109 258 56% (46%–65%) 69% (64%–75%) 0.02
Breast 44 315 55% (40%–70%) 38% (33%–44%) 0.04
Cervix 40 55 37% (21%–52%) 24% (13%–35%) 0.19
Non-Hodgkin 
lymphoma
16 62 91% (76%–100%) 65% (53%–76%) 0.05
* Regional or distant spread of disease.
† Number of cases with known stage for each cancer site.
‡ Number of cases with regional or distant spread of disease at diagnosis as a proportion of the total number 
of cases with known stage, for each cancer site, adjusted for age at diagnosis to the age distribution of non-
Indigenous cases.
§ Test for difference between proportions of Indigenous and non-Indigenous patients with advanced disease, 
adjusted for age at diagnosis.
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each cancer site. Thus while the more
advanced cancer stage at diagnosis in Indige-
nous patients for four of the five cancer sites
may explain part of their poorer survival
from cancer, it is unlikely to explain it all.
Although up to 12 years had elapsed
between diagnosis and data collection, all
but 165 records were available (12% of
eligible cases). Including these additional
cases could have changed the results of the
study to only a small extent. A data-quality
audit of the Registry for cases diagnosed in
the period 1991–1999 estimated that com-
pleteness of case ascertainment was about
94%.6 A recent project by the Registry to
identify previously unregistered cases
increased the number of registered cases
diagnosed in 1991–1999 by 3%.6 These
additional cases were not included in this
study, but would have made little difference
to the results reported here.
The degree of misclassification of Indige-
nous status was small. A data-quality audit
of the NT Cancer Registry estimated that
about 15% of Indigenous people in the
Registry were misclassified as non-Indige-
nous;6 this was reduced to about 12% for
people included in this study after examina-
tion of their medical records during data
collection. We have no data from which to
estimate the effect of Indigenous under-
identification on the difference between
Indigenous and non-Indigenous cancer sur-
vival rates. Bias in either direction could be
argued.
Cause-specific survival analysis relies on
the accuracy of recording of cause of death,
to differentiate cancer deaths from non-
cancer deaths. Cause of death was verified
during examination of medical records,
rather than relying on death registration
data recorded by the Cancer Registry. Cause-
specific analysis was also found to give
similar results to relative survival analysis
(not reported here).
Our finding that a higher proportion of
Indigenous people had localised lung cancer
compared with non-Indigenous people is
inconsistent with the findings for the other
four cancer sites. Indigenous people in the
NT have very high prevalence of chronic
respiratory disease and a high incidence of
tuberculosis; consequently, they may have
more frequent chest x-rays and other inves-
tigations as part of clinical management or
long-term follow-up and contact tracing by
the tuberculosis control program.9,10 This
might explain why they are more likely to
be diagnosed with early-stage disease. Alter-
natively, the proportion of Indigenous peo-
ple with regional disease at diagnosis may
have been underestimated if Indigenous
patients with lung cancer were less likely to
have intensive investigations, such as medi-
astinoscopy, thoracoscopy and exploratory
thoracotomy.
A reason that Indigenous people with
cancer had a later stage at diagnosis and
lower survival rates could be that all five
cancers are more “aggressive” in Indigenous
people, either because there is something
different about the biology of these cancers
in Indigenous people or because Indigenous
people are more susceptible to rapid cancer
spread. However, the distribution of histo-
logical grade was similar in Indigenous and
non-Indigenous people for all five cancer
sites.8 There was also little difference in
morphological type, except in colorectal
cancer, which was more likely to be squa-
mous cell carcinoma in Indigenous people.8
It is much more likely that more advanced
disease at diagnosis in Indigenous people is
due to late diagnosis, possibly because of
low awareness of potentially dangerous early
symptoms and tardiness in seeking medical
advice, poor access to or low quality of
primary care, diagnostic or specialist serv-
ices, or reluctance to seek attention when
symptoms cause concern because of nihilis-
tic beliefs about cancer and the chance of
cure.11-13 For breast and cervical cancer, low
participation of Indigenous women in
screening programs may also be involved.14
The 5-year cancer survival rates in non-
Indigenous people were similar to those for
Australia as a whole for cancer diagnosed in
1992–1997: colon cancer, 61.6%; rectal
cancer, 59.7%; lung cancer, 14.2%; breast
cancer, 83.3%; cervical cancer, 76.3%; non-
Hodgkin lymphoma, 69.3% (Australian
rates adjusted to the age and sex distribution
of NT Indigenous cases, from the Australian
Institute of Health and Welfare15). While
this comparison is not exact, because of the
different methods used to estimate survival
rates (relative survival for Australian rates,
and regression-modelled cause-specific sur-
vival for NT non-Indigenous rates), it does
suggest that NT cancer services can perform
at near to national levels for non-Indigenous
patients.
Although SEER summary staging is not as
detailed as staging by other systems, com-
parison of stage-adjusted hazard ratios
using summary staging and more detailed
staging indicated that summary staging pro-
vided effective adjustment for stage at diag-
nosis (results not shown). Lower stage-
adjusted cancer survival in Indigenous peo-
ple may be due to choices against more
aggressive, curative treatment (particularly
if treatment requires interstate travel);
delayed or incomplete treatment; or factors
which make Indigenous people more sus-
ceptible to the life-threatening complica-
tions of cancer treatment. The latter could
include presence of other chronic diseases;
heavy alcohol and tobacco consumption;
and poor housing and environmental con-
ditions, which increase the risk of infectious
diseases during and after chemotherapy and
radiotherapy.16,17
Our results suggest that health services
apparently could, and should, be perform-
ing better than they currently are for Indige-
nous people with cancer in the NT, and
probably elsewhere in Australia. In the NT,
Indigenous people are more likely to be
diagnosed late and, once diagnosed, have a
lower chance of cure than non-Indigenous
people. The reasons for later diagnosis and
lower survival for Indigenous patients
should be identified and remedied.
This study has demonstrated that analysis
and reporting of cancer stage at diagnosis
and cancer survival can be used to assess the
performance of the NT health services in
providing cancer diagnosis and treatment
services to Indigenous people. Data sources
are available for the same purpose from
cancer registries in other States, but have
either not been analysed or are too limited
by inadequacy of identification of Indige-
nous people to be useful. These limitations
should be remedied as soon as possible so
that the performance of cancer services for
Indigenous Australians can be measured
and improved nationally and, on the evi-
dence of our data, urgently.
3 Adjusted cause-specific 5-year 
cancer survival rates,* by cancer 
site and Indigenous status
Site
Non-
Indigenous Indigenous
Colon and rectum 55.0% 30.7%
Lung 11.5% 5.2%
Breast 83.7% 67.5%
Cervix 70.0% 27.1%
Non-Hodgkin 
lymphoma
65.2% 16.3%
* Derived from Cox regression models, adjusted for 
age at diagnosis and stage at diagnosis; 
confidence intervals could not be calculated.
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